Chevalier T, Daste A, Saada-Bouzid E, et al. - Researchers performed a multicenter retrospective study to assess the value of continuing cetuximab in association with paclitaxel (P) beyond progression after an EXTREME chemotherapy regimen +/- cetuximab as maintenance in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), as well as to identify the prognostic factors and predictive factors for response to the paclitaxel + cetuximab (PC) combination and evaluate safety. Of the 340 patients identified, 262 were included in the analysis, with 165 receiving PC and 97 receiving P. In multivariate analysis, PC was linked to better progression-free survival and overall survival (OS). Previous maintenance of cetuximab for more than 3 months was predictive of the better OS with PC. Although continuing cetuximab in combination with paclitaxel after EXTREME provides only a marginal benefit, it may be an appealing option for certain patients.